![]() Often identified as one of the more common symptoms among patients with rheumatic diseases, fatigue also stands out as one of the most important patient-reported outcome measures alongside pain and physical function. ![]() “Simponi Aria is also the only biologic to show improvement in both physical and emotional well-being as measured by physical and mental component summary scores across PsA, RA and based on the 36-item short form health survey (SF-36).” “We were happy to learn that the FDA approved an update to the Simponi Aria label that states improvement in fatigue, as measured by FACIT-F, for adult patients with active PsA and with moderately to severely active RA in combination with methotrexate,” Andrew Greenspan, MD, vice president of United States medical affairs at Janssen Immunology, told Healio Rheumatology. “Many studies confirm what our own members with psoriatic and rheumatoid arthritis tell us - fatigue is incredibly common and impacts a person’s quality of life and their ability to manage their daily activities,” Seth D. This label expansion makes golimumab (Simponi Aria) the first TNF inhibitor approved to include fatigue improvement in its labeling, and only the second biologic overall, following the approval of guselkumab (Tremfya, Janssen), an IL-23 inhibitor, in July 2020. The FDA has approved a label update for Janssen’s golimumab to include language that treatment alongside methotrexate improves fatigue in patients with active psoriatic arthritis and moderately to severely active rheumatoid arthritis. ![]() ![]() If you continue to have this issue please contact to Healio ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |